The Roles of MDM2 and MDMX Phosphorylation in Stress Signaling to p53

Genes and Cancer

Volumn 3, Issue 3-4, 2012, Pages 274-282

  Chen, Jiandong ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

MDM2; MDMX; p53; phosphorylation; ubiquitination

Indexed keywords

ABELSON KINASE; ARF PROTEIN; ATM PROTEIN; CASEIN KINASE IALPHA; CHECKPOINT KINASE 2; DNA; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RIBOSOME PROTEIN; UBIQUITIN PROTEIN LIGASE E3;

ALLOSTERISM; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL COMMUNICATION; CELL STRESS; CELLULAR DISTRIBUTION; DIMERIZATION; DNA DAMAGE; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84875535434     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912454733     Document Type: Article

References (126)

1. Vousden KH,Lane DP.p53 in health and disease.Nat Rev Mol Cell Biol. 2007;8:275-83.
2. Kubbutat MH,Jones SN,Vousden KH.Regulation of p53 stability by Mdm2.Nature. 1997;387:299-303.
3. Haupt Y,Maya R,Kazaz A,Oren M.Mdm2 promotes the rapid degradation of p53.Nature. 1997;387:296-9.
4. Leng RP,Lin Y,Ma W, et al.Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.Cell. 2003;112:779-91.
5. Dornan D,Wertz I,Shimizu H, et al.The ubiquitin ligase COP1 is a critical negative regulator of p53.Nature. 2004;429:86-92.
6. Montes de Oca Luna R,Wagner DS,Lozano G.Rescue of early embryonic lethality in Mdm2-deficient mice by deletion of p53.Nature. 1995;378:203-6.
7. Grier JD,Xiong S,Elizondo-Fraire AC,Parant JM,Lozano G.Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.Mol Cell Biol. 2006;26:192-8.
8. Jones SN,Roe AE,Donehower LA,Bradley A.Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.Nature. 1995;378:206-8.
9. Vassilev LT,Vu BT,Graves B, et al.In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.Science. 2004;303:844-8.
10. Shangary S,Qin D,McEachern D, et al.Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.Proc Natl Acad Sci U S A. 2008;105:3933-8.
11. Shvarts A,Steegenga WT,Riteco N, et al.MDMX: a novel p53-binding protein with some functional properties of MDM2.EMBO J. 1996;15:5349-57.
12. Finch RA,Donoviel DB,Potter D, et al.Mdmx is a negative regulator of p53 activity in vivo.Cancer Res. 2002;62:3221-5.
13. Migliorini D,Lazzerini Denchi E,Danovi D, et al.Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development.Mol Cell Biol. 2002;22:5527-38.
14. Parant JM,Reinke V,Mims B,Lozano G.Organization, expression, and localization of the murine Mdmx gene and pseudogene.Gene. 2001;270:277-83.
15. Xiong S,Van Pelt CS,Elizondo-Fraire AC,Liu G,Lozano G.Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.Proc Natl Acad Sci U S A. 2006;103:3226-31.
16. Maetens M,Doumont G,Clercq SD, et al.Distinct roles of Mdm2 and Mdm4 in red cell production.Blood. 2007;109:2630-3.
17. Steinman HA,Hoover KM,Keeler ML,Sands AT,Jones SN.Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.Oncogene. 2005;24:7935-40.
18. Li B,Cheng Q,Li Z,Chen J.p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors.Cell Cycle. 2010;9:1411-20.
19. Phillips A,Teunisse A,Lam S, et al.HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.J Biol Chem. 2010;285:29111-27.
20. Fang S,Jensen JP,Ludwig RL,Vousden KH,Weissman AM.Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.J Biol Chem. 2000;275:8945-51.
21. Honda R,Tanaka H,Yasuda H.Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.FEBS Lett. 1997;420:25-7.
22. Sdek P,Ying H,Chang DL, et al.MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein.Mol Cell. 2005;20:699-708.
23. Kawai H,Wiederschain D,Yuan ZM.Critical contribution of the MDM2 acidic domain to p53 ubiquitination.Mol Cell Biol. 2003;23:4939-47.
24. Meulmeester E,Frenk R,Stad R, et al.Critical role for a central part of Mdm2 in the ubiquitylation of p53.Mol Cell Biol. 2003;23:4929-38.
25. Wang C,Ivanov A,Chen L, et al.MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.EMBO J. 2005;24:3279-90.
26. Sui G,Affar el B,Shi Y, et al.Yin Yang 1 is a negative regulator of p53.Cell. 2004;117:859-72.
27. Chen L,Li Z,Zwolinska AK, et al.MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output.EMBO J. 2010;29:2538-52.
28. Hu M,Gu L,Li M,Jeffrey PD,Gu W,Shi Y.Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.PLoS Biol. 2006;4:e27.
29. Zhang Y,Wolf GW,Bhat K, et al.Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway.Mol Cell Biol. 2003;23:8902-12.
30. Midgley CA,Desterro JM,Saville MK, et al.An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.Oncogene. 2000;19:2312-23.
31. Ma J,Martin JD,Zhang H, et al.A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.Biochemistry. 2006;45:9238-45.
32. Yu GW,Rudiger S,Veprintsev D,Freund S,Fernandez-Fernandez MR,Fersht AR.The central region of HDM2 provides a second binding site for p53.Proc Natl Acad Sci U S A. 2006;103:1227-32.
33. Burch LR,Midgley CA,Currie RA,Lane DP,Hupp TR.Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA.FEBS Lett. 2000;472:93-8.
34. Cross B,Chen L,Cheng Q,Li B,Yuan ZM,Chen J.Inhibition of p53 DNA binding function by the MDM2 protein acidic domain.J Biol Chem. 2011;286:16018-29.
35. Sasaki M,Nie L,Maki CG.MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation.J Biol Chem. 2007;282:14626-34.
36. Dunker AK,Silman I,Uversky VN,Sussman JL.Function and structure of inherently disordered proteins.Curr Opin Struct Biol. 2008;18:756-64.
37. Dyson HJ,Wright PE.Intrinsically unstructured proteins and their functions.Nat Rev Mol Cell Biol. 2005;6:197-208.
38. Badciong JC,Haas AL.MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination.J Biol Chem. 2002;277:49668-75.
39. Francoz S,Froment P,Bogaerts S, et al.Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.Proc Natl Acad Sci U S A. 2006;103:3232-7.
40. Gilkes DM,Chen L,Chen J.MDMX regulation of p53 response to ribosomal stress.EMBO J. 2006;25:5614-25.
41. Toledo F,Krummel KA,Lee CJ, et al.A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.Cancer Cell. 2006;9:273-85.
42. Pan Y,Chen J.MDM2 promotes ubiquitination and degradation of MDMX.Mol Cell Biol. 2003;23:5113-21.
43. Linke K,Mace PD,Smith CA,Vaux DL,Silke J,Day CL.Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.Cell Death Differ. 2008;15:841-8.
44. Uldrijan S,Pannekoek WJ,Vousden KH.An essential function of the extreme C-terminus of MDM2 can be provided by MDMX.EMBO J. 2007;26:102-12.
45. Tanimura S,Ohtsuka S,Mitsui K,Shirouzu K,Yoshimura A,Ohtsubo M.MDM2 interacts with MDMX through their RING finger domains.FEBS Lett. 1999;447:5-9.
46. Linares LK,Hengstermann A,Ciechanover A,Muller S,Scheffner M.HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.Proc Natl Acad Sci U S A. 2003;100:12009-14.
47. Gu J,Kawai H,Nie L, et al.Mutual dependence of MDM2 and MDMX in their functional inactivation of p53.J Biol Chem. 2002;277:19251-4.
48. Wang X,Wang J,Jiang X.MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.J Biol Chem. 2011;286:23725-34.
49. Okamoto K,Taya Y,Nakagama H.Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.FEBS Lett. 2009;583:2710-4.
50. Kawai H,Lopez-Pajares V,Kim MM,Wiederschain D,Yuan ZM.RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity.Cancer Res. 2007;67:6026-30.
51. Huang L,Yan Z,Liao X, et al.The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo.Proc Natl Acad Sci U S A. 2011;108:12001-6.
52. Sherr CJ.Divorcing ARF and p53: an unsettled case.Nat Rev Cancer. 2006;6:663-73.
53. Zhang Y,Lu H.Signaling to p53: ribosomal proteins find their way.Cancer Cell. 2009;16:369-77.
54. Kastan MB,Zhan Q,El-Deiry WS, et al.A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.Cell. 1992;71:587-97.
55. Shiloh Y.ATM and related protein kinases: safeguarding genome integrity.Nat Rev Cancer. 2003;3:155-68.
56. Ciccia A,Elledge SJ.The DNA damage response: making it safe to play with knives.Mol Cell. 2010;40:179-204.
57. Banin S,Moyal L,Shieh S, et al.Enhanced phosphorylation of p53 by ATM in response to DNA damage.Science. 1998;281:1674-7.
58. Shieh SY,Ikeda M,Taya Y,Prives C.DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.Cell. 1997;91:325-34.
59. Chehab NH,Malikzay A,Appel M,Halazonetis TD.Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53.Genes Dev. 2000;14:278-88.
60. Shieh SY,Ahn J,Tamai K,Taya Y,Prives C.The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.Genes Dev. 2000;14:289-300.
61. Ashcroft M,Kubbutat MH,Vousden KH.Regulation of p53 function and stability by phosphorylation.Mol Cell Biol. 1999;19:1751-8.
62. Blattner C,Tobiasch E,Litfen M,Rahmsdorf HJ,Herrlich P.DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation.Oncogene. 1999;18:1723-32.
63. Dumaz N,Meek DW.Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2.EMBO J. 1999;18:7002-10.
64. Chao C,Herr D,Chun J,Xu Y.Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression.EMBO J. 2006;25:2615-22.
65. MacPherson D,Kim J,Kim T, et al.Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23.EMBO J. 2004;23:3689-99.
66. Chao C,Hergenhahn M,Kaeser MD, et al.Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses.J Biol Chem. 2003;278:41028-33.
67. Maya R,Balass M,Kim ST, et al.ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.Genes Dev. 2001;15:1067-77.
68. Shinozaki T,Nota A,Taya Y,Okamoto K.Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export.Oncogene. 2003;22:8870-80.
69. Sionov RV,Coen S,Goldberg Z, et al.c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination.Mol Cell Biol. 2001;21:5869-78.
70. Goldberg Z,Vogt Sionov R,Berger M, et al.Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation.EMBO J. 2002;21:3715-27.
71. Cheng Q,Chen L,Li Z,Lane WS,Chen J.ATM activates p53 by regulating MDM2 oligomerization and E3 processivity.EMBO J. 2009;28:3857-67.
72. Iakoucheva LM,Radivojac P,Brown CJ, et al.The importance of intrinsic disorder for protein phosphorylation.Nucleic Acids Res. 2004;32:1037-49.
73. Cheng Q,Cross B,Li B,Chen L,Li Z,Chen J.Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage.Mol Cell Biol. 2011;31:4951-63.
74. Dueber EC,Schoeffler AJ,Lingel A, et al.Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination.Science. 2011;334:376-80.
75. Deshaies RJ,Joazeiro CA.RING domain E3 ubiquitin ligases.Annu Rev Biochem. 2009;78:399-434.
76. Nikolay R,Wiederkehr T,Rist W,Kramer G,Mayer MP,Bukau B.Dimerization of the human E3 ligase CHIP via a coiled-coil domain is essential for its activity.J Biol Chem. 2004;279:2673-8.
77. Mace PD,Linke K,Feltham R, et al.Structures of the cIAP2 RING domain reveal conformational changes associated with ubiquitin-conjugating enzyme (E2) recruitment.J Biol Chem. 2008;283:31633-40.
78. Vander Kooi CW,Ohi MD,Rosenberg JA, et al.The Prp19 U-box crystal structure suggests a common dimeric architecture for a class of oligomeric E3 ubiquitin ligases.Biochemistry. 2006;45:121-30.
79. David Y,Ziv T,Admon A,Navon A.The E2 ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines.J Biol Chem. 2010;285:8595-604.
80. Brzovic PS,Lissounov A,Christensen DE,Hoyt DW,Klevit RE.A UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination.Mol Cell. 2006;21:873-80.
81. Poyurovsky MV,Priest C,Kentsis A, et al.The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity.EMBO J. 2007;26:90-101.
82. Cheng Q,Chen L,Li Z,Lane WS,Chen J.ATM activates p53 by regulating MDM2 oligomerization and E3 processivity.EMBO J. 2009;28:3857-67.
83. Kostic M,Matt T,Martinez-Yamout MA,Dyson HJ,Wright PE.Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53.J Mol Biol. 2006;363:433-50.
84. Shi D,Pop MS,Kulikov R,Love IM,Kung AL,Grossman SR.CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53.Proc Natl Acad Sci U S A. 2009;106:16275-80.
85. Wu H,Pomeroy SL,Ferreira M, et al.UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53.Nat Med. 2011;17:347-55.
86. Li M,Brooks CL,Kon N,Gu W.A dynamic role of HAUSP in the p53-Mdm2 pathway.Mol Cell. 2004;13:879-86.
87. Cummins JM,Rago C,Kohli M,Kinzler KW,Lengauer C,Vogelstein B.Tumour suppression: disruption of HAUSP gene stabilizes p53.Nature. 2004;428:.
88. Tang J,Qu LK,Zhang J, et al.Critical role for Daxx in regulating Mdm2.Nat Cell Biol. 2006;8:855-62.
89. Maya R,Oren M.Unmasking of phosphorylation-sensitive epitopes on p53 and Mdm2 by a simple Western-phosphatase procedure.Oncogene. 2000;19:3213-5.
90. de Toledo SM,Azzam EI,Dahlberg WK,Gooding TB,Little JB.ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation.Oncogene. 2000;19:6185-93.
91. Cheng Q,Chen J.The phenotype of MDM2 auto-degradation after DNA damage is due to epitope masking by phosphorylation.Cell Cycle. 2011;10:1162-6.
92. Wu L,Levine AJ.Differential regulation of the p21/WAF-1 and Mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the Mdm2 gene.Mol Med. 1997;3:441-51.
93. Blattner C,Hay T,Meek DW,Lane DP.Hypophosphorylation of Mdm2 augments p53 stability.Mol Cell Biol. 2002;22:6170-82.
94. Winter M,Milne D,Dias S, et al.Protein kinase CK1delta phosphorylates key sites in the acidic domain of murine double-minute clone 2 protein (MDM2) that regulate p53 turnover.Biochemistry. 2004;43:16356-64.
95. Kulikov R,Boehme KA,Blattner C.Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance.Mol Cell Biol. 2005;25:7170-80.
96. Inuzuka H,Tseng A,Gao D, et al.Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase.Cancer Cell. 2010;18:147-59.
97. Kulikov R,Letienne J,Kaur M,Grossman SR,Arts J,Blattner C.Mdm2 facilitates the association of p53 with the proteasome.Proc Natl Acad Sci U S A. 2010;107:10038-43.
98. Shimizu H,Burch LR,Smith AJ, et al.The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.J Biol Chem. 2002;277:28446-58.
99. Kulikov R,Winter M,Blattner C.Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation.J Biol Chem. 2006;281:28575-83.
100. de Graaf P,Little NA,Ramos YF,Meulmeester E,Letteboer SJ,Jochemsen AG.Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2.J Biol Chem. 2003;278:38315-24.
101. Kawai H,Wiederschain D,Kitao H,Stuart J,Tsai KK,Yuan ZM.DNA damage-induced MDMX degradation is mediated by MDM2.J Biol Chem. 2003;278:45946-53.
102. Chen L,Gilkes DM,Pan Y,Lane WS,Chen J.ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.EMBO J. 2005;24:3411-22.
103. Pereg Y,Shkedy D,de Graaf P, et al.Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage.Proc Natl Acad Sci U S A. 2005;102:5056-61.
104. Jin Y,Dai MS,Lu SZ, et al.14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation.EMBO J. 2006;25:1207-18.
105. LeBron C,Chen L,Gilkes DM,Chen J.Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3.EMBO J. 2006;25:1196-206.
106. Zuckerman V,Lenos K,Popowicz GM, et al.c-Abl phosphorylates Hdmx and regulates its interaction with p53.J Biol Chem. 2009;284:4031-9.
107. Mayo LD,Donner DB.A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.Proc Natl Acad Sci U S A. 2001;98:11598-603.
108. Zhou BP,Liao Y,Xia W,Zou Y,Spohn B,Hung MC.HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.Nat Cell Biol. 2001;3:973-82.
109. Milne D,Kampanis P,Nicol S, et al.A novel site of AKT-mediated phosphorylation in the human MDM2 onco-protein.FEBS Lett. 2004;577:270-6.
110. Ashcroft M,Ludwig RL,Woods DB, et al.Phosphorylation of HDM2 by Akt.Oncogene. 2002;21:1955-62.
111. Li C,Chen L,Chen J.DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms.Mol Cell Biol. 2002;22:7562-71.
112. Migliorini D,Danovi D,Colombo E,Carbone R,Pelicci PG,Marine JC.Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation.J Biol Chem. 2002;277:7318-23.
113. Okamoto K,Kashima K,Pereg Y, et al.DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation.Mol Cell Biol. 2005;25:9608-20.
114. Zhang X,Lin L,Guo H, et al.Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response.Cancer Res. 2009;69:7960-8.
115. Waning DL,Lehman JA,Batuello CN,Mayo LD.c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation.J Biol Chem. 2011;286:216-22.
116. Meulmeester E,Maurice MM,Boutell C, et al.Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2.Mol Cell. 2005;18:565-76.
117. Pereg Y,Lam S,Teunisse A, et al.Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage.Mol Cell Biol. 2006;26:6819-31.
118. Wang YV,Leblanc M,Wade M,Jochemsen AG,Wahl GM.Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases.Cancer Cell. 2009;16:33-43.
119. Chen L,Li C,Pan Y,Chen J.Regulation of p53-MDMX interaction by casein kinase 1 alpha.Mol Cell Biol. 2005;25:6509-20.
120. Knippschild U,Gocht A,Wolff S,Huber N,Lohler J,Stoter M.The casein kinase 1 family: participation in multiple cellular processes in eukaryotes.Cell Signal. 2005;17:675-89.
121. Elyada E,Pribluda A,Goldstein RE, et al.CKIalpha ablation highlights a critical role for p53 in invasiveness control.Nature. 2011;470:409-13.
122. Li X,Gilkes D,Li B, et al.Abnormal MDMX degradation in tumor cells due to ARF deficiency.Oncogene. 2011;:.
123. Wallace M,Worrall E,Pettersson S,Hupp TR,Ball KL.Dual-site regulation of MDM2 E3-ubiquitin ligase activity.Mol Cell. 2006;23:251-63.
124. Wawrzynow B,Pettersson S,Zylicz A, et al.A function for the RING finger domain in the allosteric control of MDM2 conformation and activity.J Biol Chem. 2009;284:11517-30.
125. Dang J,Kuo ML,Eischen CM,Stepanova L,Sherr CJ,Roussel MF.The RING domain of Mdm2 can inhibit cell proliferation.Cancer Res. 2002;62:1222-30.
126. Burke JR,Deshong AJ,Pelton JG,Rubin SM.Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding.J Biol Chem. 2010;285:16286-93.